Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related Posts

Autodesk says it’s cutting 9% of its workforce, and shares rise

Autodesk says it’s cutting 9% of its workforce, and sha...

South Korea's pension fund logs record 15% investment return in 2024

South Korea's pension fund logs record 15% investment r...

Japan factory output contracts as expected in Jan, retail sales jump

Japan factory output contracts as expected in Jan, reta...

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

HP Inc. was proactive about the impact of tariffs, and it may be paying off

HP Inc. was proactive about the impact of tariffs, and ...

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through